A common acne medication may soon offer hope to millions of men facing hair loss. Ireland-based Cosmo Pharmaceuticals reported that clascoterone, a topical drug originally approved for acne, produced significant hair growth in two large Phase III trials.
Hair loss has long frustrated men, with treatments largely limited to minoxidil or oral anti-androgens such as finasteride. Many lotions, oils, and supplements promise results but rarely deliver noticeable regrowth. Clascoterone—FDA-approved in 2020 for acne—is emerging as a potential topical solution for hair restoration.
How it Works
Clascoterone blocks DHT, the hormone responsible for shrinking hair follicles, directly at the scalp. Unlike oral treatments, it acts locally, helping men avoid systemic side effects, including sexual dysfunction. Cosmo Pharmaceuticals says this targeted approach could be the first major innovation in male hair-loss treatment in over 30 years.
Phase III Trial Results
Two Phase III trials involved 1,500 men with androgenetic alopecia (male pattern baldness):
- Trial 1: Hair regrowth increased by 539% compared to placebo
- Trial 2: Hair regrowth increased by 168%
Giovanni Di Napoli, CEO of Cosmo Pharmaceuticals, called the results “a fundamentally better treatment paradigm” for patients. Experts suggest clascoterone could become the first major new therapy for male pattern baldness in decades.
Why it Matters
Current options either slow hair loss or carry potential side effects. Clascoterone offers:
- Real hair regrowth, not just maintenance
- Safer, easy-to-apply topical use
- An alternative to ineffective oils, creams, and supplements
Who Could Benefit
Men in early to mid-stages of hair loss may see the greatest gains. Male pattern baldness typically progresses in seven stages, from thinning at the temples to widespread crown loss.
Caution and Unknowns
Experts warn:
Percent improvements may overstate visual impact
Long-term effects are unclear; trials lasted six months
Regulatory approval is still pending
Clascoterone targets androgen-driven hair loss, not autoimmune or scarring types
Related topic：
